You are here: Home: YIR: Multiple Myeloma: Priority 2

PRIORITY 2 PUBLICATIONS / PRESENTATIONS ( RECOMMENDED)

 

Michele Cavo et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25(17):2434-41.

Jeffrey A Zonder et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): Results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. Proc ASH 2007.

Amitabha Mazumder et al. The effect of induction therapy with novel agents on stem cell mobilization in multiple myeloma. Proc ASCO 2007.

Marco Ladetto et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Proc ASH 2007.

Cyrille Hulin et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥ 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Proc ASH 2007.

Paul G Richardson et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007;137(5):429-35.

Jesus F San-Miguel et al. Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia 2008;22(4):842-9.

Paul G Richardson et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007;110(10):3557-60.

Bart Barlogie et al. Incorporating bortezomib into up-front treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007;138(2):176-85.

Rakesh Popat et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: Updated results after long-term follow-up. Br J Haematol 2008;141(4):512-6.

Antonio Palumbo et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA — Italian Multiple Myeloma Network. J Clin Oncol 2007;25(28):4459-65.

Antonio Palumbo et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414-23.

Ashraf Badros et al. Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. Cancer 2007;110(5):1042-9.

Verena Sagaster et al. Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21(1):164-8.
Table of Contents Top of Page